Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Psychedelic State(s) of America
Psa Announcements2 min read

Track Psychedelic and Cannabis Stocks Live in PSA's "Forever Paywall-Free" Market Directory

48 psychedelic, cannabis and neuro-pharma listings with live charts, company profiles, an earnings calendar and portfolio tools, open to every reader.

By PSA Media Team

Contributor ·

PSA Market Directory hero: a live pulse chart tracing green and red over a purple fill under the title Market Directory. Tracking the pulse of psychedelic, cannabis, and neuro-pharma stocks.

Fuel the Future of Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate at the link below.

Donate to PSA

Tracking the pulse of psychedelic, cannabis, & neuro‑pharma stocks.

Inside PSA's Market Directory

Every psychedelic, cannabis and neuro‑pharma stock PSA follows now sits on one free page. The Market Directory tracks 48 listings, from Compass Pathways and GH Research to Trulieve, Eli Lilly and the AdvisorShares Psychedelics ETF (PSIL), with live prices and charts for each one.

It's open to every reader. There's no sign‑in to browse, no paywall, and no company pays to be listed.

PSA covers the decisions that move this sector, from FDA reviews to drug scheduling. The directory puts the market side of those stories next to our reporting.

What you can do there

Search and filter the full list. Find any company by ticker, name or former name, then narrow by sector: cannabis (24), biotech (7), psychedelics (7), pharma (4) and funds and ETFs (4), plus a clinic operator and an Australian psychedelic biotech.

Open a company profile. Each listing has its own page with a live chart, links to the company's website and investor relations, and the PSA stories, commentary and NewsWire items that mention it.

Compare up to four companies. Read their charts and fundamentals side by side in one row.

Test a pick against the market. Stock Analysis takes an amount and a date range and shows how up to five listings did against the S&P 500 and the Nasdaq, using daily closing prices adjusted for splits and dividends.

Check the Market Calendar. Upcoming earnings dates, Federal Reserve meetings and U.S. market holidays, all in one place.

Save a watchlist, a portfolio and price alerts. With a free reader account, star the stocks you follow, log your holdings to see their value and gain or loss, and set an alert on any listing.

Follow crypto, too. 17 major coins, from Bitcoin and Ethereum to Solana, with prices that refresh every 15 seconds.

Open the Market Directory →

Earnings dates are provider estimates, not company announcements.

For information only, not investment advice.

With Psilocybin Doses Projected Up to $22,000, Usona and Compass Race Toward FDA Approval
PSA's Sunday Sound‑Off, November 8, 2026

FDA answers lawmakers on psychedelic trials
Weekly Psychedelic Policy Briefing, November 10, 2026

Advancing Innovation in Mental Health: An Interview with Kabir Nath, CEO of Compass Pathways

Know someone who follows this sector?

Forward this email, or send them to PsychedelicAmericas.Org to subscribe free.

Subscribe to PSA →

Share PSA With a Friend →

Not what you’re looking to read? We get it!

Pick the PSA Content you want to see by updating your preferences at the link below

Support independent journalism

The PSA Media Fund

Psychedelic State(s) of America isn’t another news outlet — it’s a vessel to help the fantastic independent psychedelic and cannabis media organizations that already exist do more of what they do best. Our coverage is reader-funded, and your support keeps news, commentary, and education on psychedelic policy free for everyone.

Donate to PSA

Until next time,
The Psychedelic State(s) of America Team

Your inbox, your call

Choose what PSA sends you

PSA publishes several series. Keep the ones you want and drop the rest, without unsubscribing from PSA. Choose your PSA series

Read our Editorial StandardsRequest a correction

You read to the end

Get PSA News & Investigations in your inbox

Free to read. Free to subscribe.

Related stories

Picked by shared tags, desk, and byline.